Table 3 The summary of research on cuproptosis-associated RNA biomarkers in HCC
Researchers | Biomarkers of RNA | Findings and Significance of the Research | References |
|---|---|---|---|
Genhao Zhang et al | lncRNAs (AC099329.2, AC138904.1, AC145343.1, DNMBP-AS1, DEPDC1-AS1, GIHCG) | Selected six lncRNA linked to cuproptosis and built a lncRNA profile to predict the prognosis of immunotherapy in HCC | |
Qiongyue Zhang et al | lncRNAs (AC003093.1, AC015819.1, AL122035.1, AL590705.3, and MKLN1-AS) | Selected five lncRNAs that could be used in HCC immunotherapy and targeted therapy evaluation, immune cell activity, and function prediction | |
Hongfei Zhu et al | lncRNAs (AC005479.2, AC009974.2, GSEC, AC026412.3, AC245060.7, AL031985.3, AL158166.1, AL365361.1, LINC00426) | Built the CRlncSig to predict the prognosis of immunotherapy in HCC | |
Shujia Chen et al | lncRNAs (AC019069.1, AC079209.1, AC105020.5, HCG15, LINC01515) | Those lncRNAs are associated with TME and expressions of key immune checkpoints | |
Lan Luo et al | lncRNAs (AC012073.1, AC099850.3, AL031985.3, KDM4A-AS1, MIR210HG, MKLN1-AS, and PLBD1AS1) | Built the CRLRSM, and the high expression of these 7 lncRNAs is associated with poor prognosis in HCC | |
Ze Jin et al | miRNAs | The first research focused on miRNAs of cuproptosis in HCC and the CRMs associated with the prognosis of HCC |